<table>
<thead>
<tr>
<th><strong>Clinical Pharmacology NDA Review</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NDA/SDN</strong></td>
</tr>
<tr>
<td><strong>Type/Category</strong></td>
</tr>
<tr>
<td><strong>Brand Name</strong></td>
</tr>
<tr>
<td><strong>Generic Name</strong></td>
</tr>
<tr>
<td><strong>Receipt Date</strong></td>
</tr>
<tr>
<td><strong>PDUFA Date</strong></td>
</tr>
<tr>
<td><strong>Proposed Indication</strong></td>
</tr>
<tr>
<td><strong>Dosage Form</strong></td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
</tr>
<tr>
<td><strong>Dosing Regimen and Strength</strong></td>
</tr>
<tr>
<td><strong>Applicant</strong></td>
</tr>
<tr>
<td><strong>OND Division</strong></td>
</tr>
<tr>
<td><strong>OCP Divisions</strong></td>
</tr>
<tr>
<td><strong>OCP Reviewers</strong></td>
</tr>
<tr>
<td><strong>OCP Team Leaders</strong></td>
</tr>
</tbody>
</table>
# Table of Contents

1 EXECUTIVE SUMMARY .................................................................................................................. 3  
1.1 RECOMMENDATIONS .................................................................................................................. 3  
1.2 PHASE 4 REQUIREMENTS AND COMMITMENTS ........................................................................ 3  
1.3 SUMMARY OF IMPORTANT CLINICAL PHARMACOLOGY FINDINGS ......................................... 4  
2 QUESTION-BASED REVIEW .......................................................................................................... 5  
  2.1 GENERAL ATTRIBUTES .............................................................................................................. 5  
  2.2 GENERAL CLINICAL PHARMACOLOGY .................................................................................... 6  
  2.3 INTRINSIC FACTORS ................................................................................................................. 8  
  2.4 EXTRINSIC FACTORS ............................................................................................................... 8  
  2.5 GENERAL BIOPHARMACEUTICS ............................................................................................. 9  
  2.6 ANALYTICAL SECTION ............................................................................................................ 10  
3 DETAILED LABELING RECOMMENDATIONS ............................................................................. 10  
4 APPENDIX ..................................................................................................................................... 11  
  4.1 APPLICANT’S PROPOSED PACKAGE INSERT ....................................................................... 11
1 EXECUTIVE SUMMARY

The Applicant has submitted a 505(b)(2) application for the approval of barium sulfate oral suspension powder 98% w/w for use in adults for double contrast radiographic examinations of the esophagus, stomach and duodenum. No clinical or clinical pharmacology studies were performed by the applicant. The dosing, safety and efficacy data for the approval of this application is based upon Guidelines and appropriateness criteria issued by the American College of Radiology (ACR); Radiology textbooks; and published papers and review articles retrieved from the literature. Clinical pharmacology section is supported by seven literature references. Reconstitution as directed using 65 mL of potable water yields approximately 140 mL of a 0.4% w/v oral suspension (2.3 grams barium sulfate per mL). The recommended dose is 65-135 mL of the oral suspension. Barium sulfate is an insoluble compound and is biologically inert. The systemic absorption of barium sulfate is extremely limited; it is not metabolized and is eliminated unchanged in the feces.

1.1 RECOMMENDATIONS

The NDA 208-036 is acceptable from a clinical pharmacology perspective provided that the Applicant and the FDA come to an agreement regarding the labeling language.

1.2 POST-MARKETING REQUIREMENTS AND COMMITMENTS

None.

Signatures:

Reviewer: Christy S John, Ph.D. Team Leader: Gene Williams, Ph.D.
Division of Clinical Pharmacology V Division of Clinical Pharmacology V
Cc: DMIP: RPM - F Lutterodt; MO - B. Ye; MTL - A Gorovets
     DCPV: DDD - B Booth; DD - Nam A Rahman
1.3  **Summary of Important Clinical Pharmacology Findings**

The Applicant has submitted a 505(b)(2) application for the approval of barium sulfate oral suspension 98% w/w. No clinical or clinical pharmacology studies were conducted by the applicant. Barium Sulfate medical imaging products have been used since the early 1900s as radiopaque contrast agents to opacify the GI tract following oral administration (pharynx, hypopharynx, esophagus, stomach, duodenum, and small bowel exams) or rectal administration (colon and distal segments of the small bowel). The dosing, safety and efficacy data for the approval of this application is based upon Guidelines and appropriateness criteria issued by the American College of Radiology (ACR); Guidelines on the safety of contrast agents issued by the European Society of Urogenital Radiology (ESUR); Radiology textbooks; and published papers and review articles retrieved from the literature and post-marketing surveillance (PMS) database based on an estimated exposure of more than 100 patients worldwide, in the period comprised between January 1, 2009 to July 31, 2014.

E-Z-HD is a barium sulfate powder for oral suspension, 98% w/w. Reconstitution as directed using 65 mL of potable water yields approximately 140 mL of a 2.3 grams barium sulfate per mL. The recommended dose is 65-135 ml oral suspension.

The time for barium sulfate to produce adequate opacification of a GI segment varies according to the route of administration, the concentration, and the viscosity of the administered barium suspension. Maximum opacification of the esophagus, stomach, and duodenum occurs almost immediately after the oral administration of the barium sulfate suspension whereas opacification of the small bowel occurs between 15 and 90 minutes after oral administration of the barium sulfate suspension. Timing of opacification of the colon following rectal administration of the barium suspension (barium enema) depends on a number of factors such as positioning of the patient during the procedure, hydrostatic pressure, and rate of administration.

Barium sulfate is an insoluble compound and is biologically inert. The systemic absorption of barium sulfate is extremely limited; it is not metabolized and is eliminated unchanged in the feces. After oral ingestion of a barium sulfate preparation, 0.16-0.26 x 10^-6 of the ingested dose was subsequently excreted via the urinary tract whereas urinary excretion of rectally administered. Barium Sulfate was in the range of 0.02-0.09 x 10^-6 of the administered dose. The clinical significance of absorption of such small amounts is speculative; particularly in view of the presence of spectrometrically measurable trace amounts of barium in many water supplies.
2 QUESTION-BASED REVIEW

2.1 GENERAL ATTRIBUTES

2.1.1 What are the highlights of the chemistry and physical-chemical properties of the drug substance and the formulation of the drug product?

A listing of the ingredients per unit dose of E-Z-HD is provided in Table 1.

<table>
<thead>
<tr>
<th>Component number</th>
<th>Component name</th>
<th>Percentage composition (% w/w)</th>
<th>Amount (g) per unit dose (140 g)</th>
<th>Function</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b)(4)</td>
<td>Barium sulfate</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Barium sulfate</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Sorbitol</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Acacia</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Sodium citrate</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Simethicone</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Citric acid</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Polysorbate 80</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Carrageenan</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Ethyl maltol</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Saccharia sodium</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Natural and artificial strawberry flavor</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)(4)</td>
<td>Natural and artificial cherry flavor</td>
<td>USP</td>
<td>USP-NF</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.1.2 What are the proposed mechanism(s) of action and therapeutic indication(s)?

Barium sulfate use as a contrast agent is based on the high atomic number of barium which enhances the absorption of X-ray beams and allows opacification of the GI tract during conventional X-ray and computed tomography (CT) examinations. Barium sulfate is a heavy metal characterized by a high atomic number (Z=56) and a K shell binding energy (K-edge) of 37.4 keV which is close to the mean energy of most diagnostic X-ray beams and therefore ideal for absorption of X-rays. Although iodinated water soluble agents have similar characteristics (iodine atomic number and K-edge are 53 and 33.2 keV, respectively), barium sulfate products remain the preferred agents for imaging the GI tract because of greater delineation of mucosal details and resistance to dilution.

2.1.3 What are the proposed dosage(s) and route(s) of administration?

E-Z-HD is a barium sulfate powder for oral suspension, 98% w/w. Reconstitution as directed using 65 mL of potable water yields approximately 140 mL of a 8% w/v oral suspension.

Reference ID: 3805140
grams barium sulfate per mL). The recommended dose is 65-135 ml oral suspension. The current NDA is based upon literature. Doses, concentrations and volumes reported in the literature vary based upon the indication.

2.2 GENERAL CLINICAL PHARMACOLOGY

2.2.1 What are the design features of the clinical pharmacology and clinical studies used to support dosing or claims?

2.2.2 What is the basis for selecting the response endpoints or biomarkers and how are they measured in clinical pharmacology and clinical studies?

2.2.3 Are the active moieties in the plasma (or other biological fluid) appropriately identified and measured to assess pharmacokinetic parameters and exposure-response relationships?

2.2.4 Exposure-response

2.2.4.1 What are the characteristics of the exposure-response relationships (dose-response, concentration-response) for efficacy?

2.2.4.2 What are the characteristics of the exposure-response relationships (dose-response, concentration-response) for safety?

The safety, efficacy and dosing data for the approval of this application is based upon Guidelines and appropriateness criteria issued by the American College of Radiology (ACR); Guidelines on the safety of contrast agents issued by the European Society of Urogenital Radiology (ESUR); Radiology textbooks; and published papers and review articles retrieved from the literature and post-marketing surveillance (PMS) database based on an estimated exposure of more than patients worldwide in the period between January 1, 2009 to July 31, 2014. There is no dose-response relationship described in the literature.

The time for Barium sulfate to produce adequate opacification of a GI segment varies according to the route of administration, the concentration, and the viscosity of the administered barium suspension. Maximum opacification of the esophagus, stomach, and duodenum occurs almost immediately after the oral administration of the Barium Sulfate suspension whereas opacification of the small bowel occurs between 15 and 90 minutes after oral administration of the barium sulfate suspension. Timing of opacification of the colon following rectal administration of the barium suspension (barium enema) depends on a number of factors such as positioning of the patient during the procedure, hydrostatic pressure, and rate of administration.

2.2.4.3 Does this drug prolong the QT or QTc interval?

No QT study of the type recommended in FDA Guidance has been performed. Transient ECG changes are known to occur during visceral stimulation and have been reported in association
with gastroscopy and sigmoidoscopy. ECG abnormalities are more frequent in elderly patients with clinical history of cardiac disease; patient dehydration, a condition of stress and anxiety during the examination, and the concomitant administration of antispasmodic drugs may represent contributing factors to the development of arrhythmias during barium enema or enteroclysis.

2.2.4.4 Is the dose and dosing regimen selected by the applicant consistent with the known relationship between dose-concentration-response, and is there any unresolved dosing or administration issue?

There is no unresolved dose or dosing regimen issues.

2.2.5 What are the PK characteristics of the drug?

2.2.5.1 What are the single dose and multiple dose PK parameters?

2.2.5.2 How does the PK of the drug and its major active metabolites in healthy volunteers compare to that in patients?

2.2.5.3 What are the characteristics of drug absorption?

2.2.5.4 What are the characteristics of drug distribution?

Barium sulfate is an insoluble compound and is biologically inert. The systemic absorption of barium sulfate is extremely limited (see 2.2.5.7, below).

2.2.5.5 Does the mass balance study suggest renal or hepatic as the major route of elimination?

2.2.5.6 What are the characteristics of drug metabolism?

2.2.5.7 What are the characteristics of drug excretion?

Atomic absorption spectrometry has been used to measure urinary excretion of barium after oral and rectal administration of barium sulfate suspensions. After oral ingestion of a barium sulfate preparation, 0.16-0.26x10^-6 of the ingested dose was excreted via the urinary tract whereas urinary excretion of rectally administered. Barium sulfate was in the range of 0.02-0.09x10^-6 of the administered dose. By subtraction, greater than 99.99% of the dose is not absorbed. The clinical significance of absorption of such small amounts is speculative

2.2.5.8 Based on PK parameters, what is the degree of linearity or non-linearity based in the dose-concentration relationship?

2.2.5.9 How do the PK parameters change with time following chronic dosing?

2.2.5.10 What is the inter- and intra-subject variability of the PK parameters in volunteers and patients and what are the major causes of variability?

There are no PK studies reported as barium sulfate is insoluble and is not systemically absorbed.
2.3 **INTRINSIC FACTORS**

2.3.1 What intrinsic factors influence exposure and/or response, and what is the impact of any differences in exposure on effectiveness or safety responses?

2.3.2 Based upon what is known about exposure-response relationships and their variability and the groups studied, healthy volunteers vs. patients vs. specific populations, what dosage regimen adjustments, if any, are recommended for each of these groups?

No dosage regimen adjustments are recommended for specific patient populations.

2.4 **EXTRINSIC FACTORS**

2.4.1 What extrinsic factors (drugs, herbal products, diet, smoking, and alcohol use) influence dose-exposure and/or dose-response and what is the impact of any differences in exposure on response?

2.4.2 **Drug-drug interactions?**

2.4.2.1 Is there an in vitro basis to suspect in vivo drug-drug interactions?

2.4.2.2 Is the drug a substrate of CYP enzymes?

2.4.2.3 Is the drug an inhibitor and/or an inducer of CYP enzymes?

2.4.2.4 Is the drug an inhibitor and/or an inducer of transporters?

2.4.2.5 Are there other metabolic/transporter pathways that may be important?

2.4.2.6 Does the label specify co-administration of another drug and, if so, has the interaction potential between these drugs been evaluated?

2.4.2.7 What other co-medications are likely to be administered to the target population?

2.4.2.8 Are there any in vivo drug-drug interaction studies that indicate the exposure alone and/or exposure-response relationships are different when drugs are co-administered?

2.4.2.9 Is there a known mechanistic basis for pharmacodynamic drug-drug interactions?

2.4.2.10 Are there any unresolved questions related to metabolism, active metabolites, metabolic drug interactions or protein binding?

Barium sulfate is not absorbed. Further, barium sulfate is biologically inert. For both of these reasons, CYP and transporter related interactions are not expected. There are no known interactions with other medicinal products.

2.4.3 **What issues related to dose, dosing regimens, or administrations are unresolved and represent significant omissions?**

None.
2.5 **GENERAL BIOPHARMACEUTICS**

2.5.1 Based on BCS principles, in what class is this drug and formulation? What solubility, permeability and dissolution data support this classification?

2.5.2 What is the relative bioavailability of the proposed to-be-marketed formulation to the clinical trial formulation?

2.5.3 What is the effect of food on the bioavailability (BA) of the drug from the dosage form? What dosing recommendation should be made, if any, regarding administration of the product in relation to meals or meal types?

Food will not render barium sulfate soluble. The label is silent on the effect of food as well as pre-dose patient preparation (i.e., fasting prior to dosing). There is literature on the use of BaSO4 taken with food for evaluation of gastric motility, however, this is not an indication proposed by the applicant.

2.5.4 When would a fed BE study be appropriate and was one conducted?

2.5.5 How do dissolution conditions and specifications ensure in vivo performance and quality of the product?

2.5.6 If different strength formulations are not bioequivalent based on standard criteria, what clinical safety and efficacy data support the approval of various strengths of the to-be-marketed product?

2.5.7 If the NDA is for a modified release formulation of an approved immediate product without supportive safety and efficacy studies, what dosing regimen changes are necessary, if any, in the presence or absence of PK-PD relationship?

2.5.8 If unapproved products or altered approved products were used as active controls, how is BE to the ‘to-be-marketed’ product? What is the basis for using either in vitro or in vivo data to evaluate BE?

Not applicable.
2.5.9 What other significant, unresolved issues in relation to in vitro dissolution of in vivo BA and BE need to be addressed?

None.

2.6 ANALYTICAL SECTION

2.6.1 How are the active moieties identified and measured in the plasma and the other matrices?

2.6.2 Which metabolites have been selected for analysis and why?

2.6.3 For all moieties measured is free, bound or total measured?

2.6.4 What bioanalytical methods are used to assess concentrations?

2.6.4.1 What is the range of the standard curve? How does it relate to the requirements for clinical studies? What curve fitting techniques are used?

2.6.4.2 What are the lower and upper limits of quantification?

2.6.4.3 What are the accuracy, precision and selectivity at these limits?

2.6.4.4 What is the sample stability under the conditions used in the study? (long-term, freeze-thaw, sample-handling, sample transport, autosampler).

There are no analytical methods reported in literature for the determination of barium sulfate in any clinical studies reported by the applicant.

3 DETAILED LABELING RECOMMENDATIONS

Review of the package insert has yet to be finalized. See Appendix 1 for the applicant’s proposed package insert.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CHRISTY S JOHN
08/12/2015

GENE M WILLIAMS
08/12/2015
I concur with the recommendations